Tissue Regeneration Therapeutics Inc.
Tissue Regeneration Therapeutics (TRT) develops our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) technology platform, to provide licensing opportunities to collaborating partners.
Together we create cell and regenerative strategies that maximize the utility of publicly sourced tissue – for therapies that address important health care issues of today.
Together, we build very powerful biology.
NEWS!
Nov. 13, 2012 - TRT’s HUCPVCs Outperform Bone Marrow Cells in Repairing Damaged Hearts
(click to read more)
Nov. 12, 2012 - Ontario Genomics Institute Invests in Stem Cell Technology at Tissue Regeneration Therapeutics
(click to read more)
Together we create cell and regenerative strategies that maximize the utility of publicly sourced tissue – for therapies that address important health care issues of today.
Together, we build very powerful biology.
NEWS!
Nov. 13, 2012 - TRT’s HUCPVCs Outperform Bone Marrow Cells in Repairing Damaged Hearts
(click to read more)
Nov. 12, 2012 - Ontario Genomics Institute Invests in Stem Cell Technology at Tissue Regeneration Therapeutics
(click to read more)